Hypercholesterolaemia treatment greenlighted

Evolocumab, the first PCSK9 inhibitor to gain TGA approval, was formally launched in Australia this week.

The indication is for primary disease: either hetero- or homozygous familial hypercholesterolaemia, or clinical atherosclerotic CVD.

The drug is only approved for use in combination with a statin or a statin plus other lipid lowering therapies.